Search Results

Showing results 8761 - 8770 for 2021

Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Zoughbi WAl, Fox J, Beg S, Papp E...

https://pathology.weill.cornell.edu/research/publications/validation-circulating-tumor-dna-based-next-generation-sequencing-assay-cohort

Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS-NF-кB-NLRP3 Axis. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Li R, Zeng X, Yang M, Feng J, Xu...

https://pathology.weill.cornell.edu/research/publications/antidiabetic-dpp-4-inhibitors-reprogram-tumor-microenvironment-facilitates

STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Jesser EA, Brady NJ, Huggins DN,...

https://pathology.weill.cornell.edu/research/publications/stat5-activated-macrophages-breast-cancer-cell-derived-factors-and-regulates

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Moskowitz AJ, Ghione P, Jacobsen...

https://pathology.weill.cornell.edu/research/publications/phase-2-biomarker-driven-study-ruxolitinib-demonstrates-effectiveness-jakstat

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Pikman Y, Tasian SK, Sulis MLuisa...

https://pathology.weill.cornell.edu/research/publications/matched-targeted-therapy-pediatric-patients-relapsed-refractory-or-high-risk

Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. | Pathology & Laboratory Medicine

...Publication Type Journal Article Year of Publication 2021 Authors Cho C, Hilden P, Avecilla ST, Barker...

https://pathology.weill.cornell.edu/research/publications/combining-disease-risk-index-and-hematopoietic-cell-transplant-co-morbidity

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. | Roth Lab

...Publication Type Journal Article Year of Publication 2021 Authors Collins GP, Eyre TA, Schmitz-Rohmer...

https://rothlab.weill.cornell.edu/publications/phase-ii-study-assess-safety-and-efficacy-dual-mtorc12-and-pi3k-inhibitor-bimiralisib

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. | Roth Lab

...Publication Type Journal Article Year of Publication 2021 Authors Giulino-Roth L, Pei Q, Buxton A,...

https://rothlab.weill.cornell.edu/publications/subsequent-malignant-neoplasms-among-children-hodgkin-lymphoma-report-childrens

NewYork-Presbyterian Hospital Named New York’s #1 Best Hospital in U.S. News & World Report’s Best Hospitals | Newsroom | Weill Cornell Medicine

...For the 2021-22 rankings and ratings, U.S....

https://news.weill.cornell.edu/news/2021/07/newyork-presbyterian-hospital-named-new-york%E2%80%99s-1-best-hospital-in-us-news-world-report

Publications | Page 3 | Winkler Lab

...Motovilova E, Vincent J, Robb F, Taracila V, Shin J, Tan ETsoon, Sneag DB, Potter HG, Winkler SA.  2021...

https://winklerlab.weill.cornell.edu/publications?page=2&s=type&o=desc

Showing results 8761 - 8770 for 2021